申请人:Eli Lilly and Company
公开号:US05726186A1
公开(公告)日:1998-03-10
The present invention provides compounds of formula I: ##STR1## wherein X is --O-- or --S--, Y is --O--, --S--, --CH.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, or --NR.sup.5 --; R.sup.1, R.sup.2, and R.sup.3 are each independently --H, --OH, --O(C.sub.1 -C.sub.4 alkyl), --OCOC.sub.6 H.sub.5, --OCO(C.sub.1 -C.sub.6 alkyl), --OSO.sub.2 (C.sub.4 -C.sub.6 alkyl), --OSO.sub.2 CF.sub.3, Cl, or F; n is 1 or 2; W is CH.sub.2 or C.dbd.O; R.sup.4 is 1-piperidinyl, 2-oxo-1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; R.sup.5 is C.sub.1 -C.sub.3 alkyl, --COC.sub.6 H.sub.5, --CO(C.sub.1 -C.sub.6 alkyl), --C(O)OC.sub.6 H.sub.5, --C(O)O(C.sub.1 -C.sub.6 alkyl), --SO.sub.2 (C.sub.1 -C.sub.6 alkyl), --SO.sub.2 C.sub.6 H.sub.5, or --SO.sub.2 CF.sub.3 ; or a pharmaceutically acceptable salt or solvate thereof.
本发明提供了式I的化合物:##STR1## 其中X为- O-或-S-,Y为- O-,- S-,- CH.sub.2-,- CH.sub.2 CH.sub.2-,- CH.dbd.CH-或-NR.sup.5-;R.sup.1,R.sup.2和R.sup.3各自独立地为- H,- OH,- O(C.sub.1-C.sub.4烷基),- OCOC.sub.6H.sub.5,- OCO(C.sub.1-C.sub.6烷基),- OSO.sub.2(C.sub.4-C.sub.6烷基),- OSO.sub.2CF.sub.3,- Cl或- F;n为1或2;W为CH.sub.2或C.dbd.O;R.sup.4为1-哌啶基,2-氧代-1-哌啶基,1-吡咯烷基,甲基-1-吡咯烷基,二甲基-1-吡咯烷基,2-氧代-1-吡咯烷基,4-吗啉基,二甲基氨基,二乙基氨基或1-己亚甲基亚胺基;R.sup.5为C.sub.1-C.sub.3烷基,- COC.sub.6H.sub.5,- CO(C.sub.1-C.sub.6烷基),- C(O)OC.sub.6H.sub.5,- C(O)O(C.sub.1-C.sub.6烷基),- SO.sub.2(C.sub.1-C.sub.6烷基),- SO.sub.2C.sub.6H.sub.5或- SO.sub.2CF.sub.3;或其药学上可接受的盐或溶剂。